Renin-angiotensin system inhibitors mitigate radiation pneumonitis by activating ACE2-angiotensin-(1–7) axis via NF-κB/MAPK pathway

• Published in: Scientific reports 2023-05, Vol.13 (1), p.8324-8324, Article 8324
• Main Authors: Cong, Changsheng, Niu, Shiying, Jiang, Yifan, Zhang, Xinhui, Jing, Wang, Zheng, Yawen, Zhang, Xiaoyue, Su, Guohai, Zhang, Yueying, Sun, Meili
• Format: Article
• Language: English
• Subjects: 692/308; 692/4028; 692/699; ACE2; Acute Lung Injury; Angiotensin; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-converting enzyme inhibitors; Animals; Antihypertensive Agents; Coronaviruses; Endocrine system; Enzyme Inhibitors; Enzymes; Humanities and Social Sciences; Inhalation; Lung cancer; MAP kinase; Mice; multidisciplinary; NF-kappa B; NF-κB protein; Peptidyl-Dipeptidase A; Phosphorylation; Pneumonitis; Radiation; Radiation Pneumonitis; Radiation therapy; Renin; Renin-Angiotensin System; Retrospective Studies; Science; Science (multidisciplinary); Sepsis; Severe acute respiratory syndrome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-35412-0

Radiation pneumonitis (RP) affects both patients and physicians during radiation therapy for lung cancer. To date, there are no effective drugs for improving the clinical outcomes of RP. The activation of angiotensin-converting enzyme 2 (ACE2) improves experimental acute lung injury caused by severe acute respiratory syndrome coronavirus, acid inhalation, and sepsis. However, the effects and underlying mechanisms of ACE2 in RP remain unclear. Therefore, this study aimed to investigate the effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on RP and ACE2/angiotensin-(1–7)/Mas receptor pathway activation. We found that radiotherapy decreased the expression of ACE2 and that overexpression of ACE2 alleviated lung injury in an RP mouse model. Moreover, captopril and valsartan restored ACE2 activation; attenuated P38, ERK, and p65 phosphorylation; and effectively mitigated RP in the mouse model. Further systematic retrospective analysis illustrated that the incidence of RP in patients using renin-angiotensin system inhibitors (RASis) was lower than that in patients not using RASis (18.2% vs. 35.8% at 3 months, p  = 0.0497). In conclusion, the current findings demonstrate that ACE2 plays a critical role in RP and suggest that RASis may be useful potential therapeutic drugs for RP.